REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

BACKGROUND: In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinreich, David M., Sivapalasingam, Sumathi, Norton, Thomas, Ali, Shazia, Gao, Haitao, Bhore, Rafia, Xiao, Jing, Hooper, Andrea T., Hamilton, Jennifer D., Musser, Bret J., Rofail, Diana, Hussein, Mohamed, Im, Joseph, Atmodjo, Dominique Y., Perry, Christina, Pan, Cynthia, Mahmood, Adnan, Hosain, Romana, Davis, John D., Turner, Kenneth C., Baum, Alina, Kyratsous, Christos A., Kim, Yunji, Cook, Amanda, Kampman, Wendy, Roque-Guerrero, Lilia, Acloque, Gerard, Aazami, Hessam, Cannon, Kevin, Simón-Campos, J. Abraham, Bocchini, Joseph A., Kowal, Bari, DiCioccio, A. Thomas, Soo, Yuhwen, Geba, Gregory P., Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522800/
https://www.ncbi.nlm.nih.gov/pubmed/34587383
http://dx.doi.org/10.1056/NEJMoa2108163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522800/
https://www.ncbi.nlm.nih.gov/pubmed/34587383
http://dx.doi.org/10.1056/NEJMoa2108163

Ejemplares similares